Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2010 1
2012 1
2014 1
2016 1
2020 2
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Dexamethasone in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. N Engl J Med. 2021. PMID: 32678530 Free PMC article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein 75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard …
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation ( …
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. N Engl J Med. 2020. PMID: 33031652 Free PMC article. Clinical Trial.
Safety of L-proline as a stabilizer for immunoglobulin products.
Hagan JB, Wasserman RL, Baggish JS, Spycher MO, Berger M, Shashi V, Lohrmann E, Sullivan KE. Hagan JB, et al. Expert Rev Clin Immunol. 2012 Feb;8(2):169-78. doi: 10.1586/eci.11.97. Expert Rev Clin Immunol. 2012. PMID: 22288455 Review.
Widespread diversity deficits of coral reef sharks and rays.
Simpfendorfer CA, Heithaus MR, Heupel MR, MacNeil MA, Meekan M, Harvey E, Sherman CS, Currey-Randall LM, Goetze JS, Kiszka JJ, Rees MJ, Speed CW, Udyawer V, Bond ME, Flowers KI, Clementi GM, Valentin-Albanese J, Adam MS, Ali K, Asher J, Aylagas E, Beaufort O, Benjamin C, Bernard ATF, Berumen ML, Bierwagen S, Birrell C, Bonnema E, Bown RMK, Brooks EJ, Brown JJ, Buddo D, Burke PJ, Cáceres C, Cambra M, Cardeñosa D, Carrier JC, Casareto S, Caselle JE, Charloo V, Cinner JE, Claverie T, Clua EEG, Cochran JEM, Cook N, Cramp JE, D'Alberto BM, de Graaf M, Dornhege MC, Espinoza M, Estep A, Fanovich L, Farabaugh NF, Fernando D, Ferreira CEL, Fields CYA, Flam AL, Floros C, Fourqurean V, Gajdzik L, Barcia LG, Garla R, Gastrich K, George L, Giarrizzo T, Graham R, Guttridge TL, Hagan V, Hardenstine RS, Heck SM, Henderson AC, Heithaus P, Hertler H, Padilla MH, Hueter RE, Jabado RW, Joyeux JC, Jaiteh V, Johnson M, Jupiter SD, Kaimuddin M, Kasana D, Kelley M, Kessel ST, Kiilu B, Kirata T, Kuguru B, Kyne F, Langlois T, Lara F, Lawe J, Lédée EJI, Lindfield S, Luna-Acosta A, Maggs JQ, Manjaji-Matsumoto BM, Marshall A, Martin L, Mateos-Molina D, Matich P, McCombs E, McIvor A, McLean D, Meggs L, Moore S… See abstract for full author list ➔ Simpfendorfer CA, et al. Science. 2023 Jun 16;380(6650):1155-1160. doi: 10.1126/science.ade4884. Epub 2023 Jun 15. Science. 2023. PMID: 37319199
Simvastatin in the acute respiratory distress syndrome.
McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, McNally C; HARP-2 Investigators; Irish Critical Care Trials Group. McAuley DF, et al. N Engl J Med. 2014 Oct 30;371(18):1695-703. doi: 10.1056/NEJMoa1403285. Epub 2014 Sep 30. N Engl J Med. 2014. PMID: 25268516 Free article. Clinical Trial.
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS. Hagan JB, et al. J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8. J Clin Immunol. 2010. PMID: 20454851 Free PMC article. Clinical Trial.
A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized with L-proline. A prospective, open-label, multicenter, single-arm, phase III study evaluated the efficacy and safety of IgPro20 in patients with PID over 15 months. Forty-nine pati …
A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized with L-proline. A prospective, open-label …
Corticotrophin-releasing hormone (CRH)-binding protein interference with CRH antibody binding: implications for direct CRH immunoassay.
Linton EA, Perkins AV, Hagan P, Poole S, Bristow AF, Tilders F, Corder R, Wolfe CD. Linton EA, et al. J Endocrinol. 1995 Jul;146(1):45-53. doi: 10.1677/joe.0.1460045. J Endocrinol. 1995. PMID: 7561620
In this study, we tested the effect of CRH-free, native CRH-BP (6.4 nmol/l) purified from human plasma, CRH-BP diluent alone, normal human plasma (containing 5.8 nmol endogenous CRH-BP/l) and normal sheep plasma (containing no CRH-BP) on the binding of 125I-labelled …
In this study, we tested the effect of CRH-free, native CRH-BP (6.4 nmol/l) purified from human plasma, CRH-BP diluent alone, normal …